A Phase 3, Randomized, Open-Label, Controlled Study of Cabozantinib (XL184) in Combination with Atezolizumab vs Second Novel Hormonal Therapy (NHT) in Subjects with Metastatic Castration-Resistant Prostate Cancer

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-516481-11-00

Acronym

XL184-315

Enrollment

203

Registered

2024-08-28

Start date

2020-09-22

Completion date

Unknown

Last updated

2025-12-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Metastatic Castration-Resistant Prostate Cancer

Brief summary

Duration of PFS per RECIST 1.1 per BIRC, Duration of OS

Detailed description

ORR per RECIST 1.1 per BIRC

Interventions

DRUGENZALUTAMIDE

DRUGCABOMETYX 20 mg film-coated tablets

DRUGPrednison acis 5 mg

DRUGTabletten

DRUGABIRATERONE ACETATE

DRUGPrednison 5 mg GALEN® Tabletten

DRUGTecentriq 1 200 mg concentrate for solution for infusion

DRUGDecortin® 5 mg Tabletten

Eligibility

Sex/Gender

Male

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Duration of PFS per RECIST 1.1 per BIRC, Duration of OS	—

Secondary

Measure	Time frame
ORR per RECIST 1.1 per BIRC	—

Countries

Belgium, Czechia, France, Germany, Greece, Italy, Poland, Portugal, Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026